Peter Thompson Sells 48,546 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 48,546 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $44.61, for a total transaction of $2,165,637.06. Following the completion of the sale, the director directly owned 2,916,228 shares in the company, valued at approximately $130,092,931.08. This represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Down 10.9%

Shares of NASDAQ:SION opened at $40.94 on Wednesday. Sionna Therapeutics, Inc. has a 52 week low of $11.77 and a 52 week high of $48.44. The company’s 50 day moving average is $38.93 and its two-hundred day moving average is $39.48. The company has a market cap of $1.85 billion, a PE ratio of -20.99 and a beta of 1.35.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, equities research analysts expect that Sionna Therapeutics, Inc. will post -2.32 EPS for the current year.

Wall Street Analyst Weigh In

SION has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Friday. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a report on Monday, March 2nd. JonesTrading increased their price objective on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Citigroup assumed coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating on the stock. Finally, BTIG Research reaffirmed a “buy” rating and issued a $58.00 target price on shares of Sionna Therapeutics in a research report on Monday, April 27th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $53.00.

Key Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Sionna completed enrollment in the PreciSION CF Phase 2a trial for SION-719, keeping the program on schedule for summer 2026 data and reducing execution risk. Article Title
• Positive Sentiment: The company reported approximately $289.9 million in cash and cash equivalents, which it expects will fund operations into 2028, easing financing concerns. Article Title
• Neutral Sentiment: Management said topline data from SION-719 and SION-451 studies are still expected in summer 2026, keeping investors focused on future catalysts rather than immediate commercial results. Article Title
• Negative Sentiment: First-quarter EPS missed expectations, adding pressure to the stock despite pipeline progress. Article Title
• Negative Sentiment: Recent insider sales by director Peter A. Thompson and OrbiMed Advisors may also be weighing on sentiment, even though the transactions were disclosed as pre-arranged 10b5-1 trades. Article Title

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics during the 4th quarter worth approximately $36,000. Russell Investments Group Ltd. purchased a new position in Sionna Therapeutics during the 3rd quarter worth approximately $30,000. Balyasny Asset Management L.P. purchased a new position in Sionna Therapeutics during the 4th quarter worth approximately $58,000. BNP Paribas Financial Markets purchased a new position in Sionna Therapeutics during the 2nd quarter worth approximately $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics during the 4th quarter worth approximately $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.